Back to news

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

Globe Newswire•18/11/2026•03:00 ET
0

Key Highlights

  • ➤Entrada’s DMC recommended Cohort 3 initiation at 15 mg/kg
  • ➤Cohort 2 enrollment completed with eight participants at 10 mg/kg
  • ➤Cohort 2 data expected in the first half of 2027
  • ➤ENTR-601-45 is administered intravenously every six weeks

Expert Statements

Natarajan Sethuraman, President of Research and Development at Entrada Therapeutics

“We are pleased with the independent Data Monitoring Committee’s recommendation to advance our ELEVATE-45-201 study to Cohort 3 at the elevated dose of 15 mg/kg”

Natarajan Sethuraman, President of Research and Development at Entrada Therapeutics

“This study progression enables us to further evaluate the safety, pharmacokinetic and pharmacodynamic profile of ENTR-601-45 at both higher doses and exposure levels, where we expect to see meaningfully higher dystrophin production and functional benefits.”

Natarajan Sethuraman, President of Research and Development at Entrada Therapeutics

“Importantly, ENTR-601-45 is designed to significantly decrease the burden of treatment on patients and their families by supporting a dosing schedule of just once every six weeks.”

Natarajan Sethuraman, President of Research and Development at Entrada Therapeutics

“We look forward to sharing data from Cohort 2 in the first half of 2027, with Cohort 3 to follow.”

-- ELEVATE-45-201 Cohort 2 (10 mg/kg) enrollment complete with data expected in H1 2027 --

BOSTON, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent safety Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 2 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-45-201. The DMC recommended initiating Cohort 3 at the dose of 15 mg/kg, a dose escalation from 10 mg/kg in Cohort 2 and 5 mg/kg in Cohort 1. ELEVATE-45-201 is a Phase 1/2 MAD clinical study of ENTR-601-45 for the potential treatment of Duchenne muscular dystrophy (DMD) in participants with a confirmed mutation in the DMD gene amenable to exon 45 skipping.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in